BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Esophageal cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for esophageal cancer: 191 (134 sponsors; 26 newly posted in the last 180 days, 9 stopped in the last 180 days; 16 new-entrant sponsors). Momentum score 10.2, rank 66 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 74, Phase 2 66, Phase 3 21, Phase 4 0, N/A 28.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN7P3 2, NA 2, P2 311
Sichuan Baili Pharmaceutical Co., Ltd.6P3 2, P1 3, P2 102
Daiichi Sankyo3P3 2, P2 100
CSPC Megalith Biopharmaceutical Co.,Ltd.2P3 210
Merck Sharp & Dohme LLC MRK6P2 5, P3 100
Astellas Pharma Global Development, Inc.5P3 1, P2 410
Bristol-Myers Squibb BMY4NA 3, P3 111
Pfizer PFE4P1 3, P3 110
Jazz Pharmaceuticals JAZZ3P3 1, NA 1, P2 111
Beijing Konruns Pharmaceutical Co., Ltd.2P3 1, P2 101
Hansoh BioMedical R&D Company2P3 1, P2 110
Ono Pharmaceutical Co., Ltd. new entrant1P3 110
Qilu Pharmaceutical Co., Ltd.1P3 100
Shandong Boan Biotechnology Co., Ltd1P3 100
Shanghai JMT-Bio Inc.1P3 100
SOFIE1P3 100
Sunshine Lake Pharma Co., Ltd. SBFM1P3 100
Eli Lilly and Company LLY5P1 502
Chongqing Precision Biotech Co., Ltd3P1 301
Seagen, a wholly owned subsidiary of Pfizer3P2 1, P1 200
SystImmune Inc.3P1 301
AbbVie ABBV2P1 200
BeOne Medicines ONC2P2 210
Exelixis EXEL2P1 201
I-Mab Biopharma US Limited2P1 1, P2 101

New-entrant sponsors: Ono Pharmaceutical Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2AP Biosciences Inc.NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamrecruiting168
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06008054 A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, CoEsophageal Cancer; Gastric Cancer; Colorectal Cancerrecruiting376
2026-12 est.P2/P3RemeGen Co., Ltd.NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapGastric Cancer; Gastroesophageal Junction Adenocarcinomarecruiting90
2026-12 est.P2Qilu Pharmaceutical Co., Ltd.NCT06942767 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or GastroesophagGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinomanot yet recruiting100
2026-12 est.P1/P2One-carbon Therapeutics ABNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid TumorsSolid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung recruiting43
2026-12 est.P2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersGastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ducnot yet recruiting300
2026-12-30 est.P3Beijing Konruns Pharmaceutical Co., Ltd.NCT06194734 A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerEsophageal Squamous Cell Carcinomarecruiting490
2026-12-30 est.P3AskGene Pharma, Inc.NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaGastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinomaactive not recruiting780
2026-12-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinomaactive not recruiting464
2026-12-30 est.P1/P2Astellas Pharma Global Development, Inc.NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metastaactive not recruiting240
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-01-11 est.P3FutureGen Biopharmaceutical (Beijing) Co., LtdNCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable orLocally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metastarecruiting486
2027-01-30 est.P3Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06656091 A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell CarcinomaAdvanced Oesophageal Squamous Cell Carcinomanot yet recruiting450
2027-02 est.P1/P2Lumicell, Inc.NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersColorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Canceractive not recruiting66
2027-02 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07367516 Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal CancerEsophageal Cancerrecruiting105

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-17 est.P2AstraZeneca AZNNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcirecruiting226
2026-11 est.P3AkesoNCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaGastric and Gastroesophageal Junction Adenocarcinomarecruiting506
2026-10-31 est.P2Shanghai Henlius BiotechNCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyEsophageal Cancerrecruiting102
2026-10-19P3Merck Sharp & Dohme LLC MRKNCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Gastroesophageal Canceractive not recruiting473
2026-10-01 est.P2Taiho Oncology, Inc.NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adeactive not recruiting53
2026-10-01P1/P2Merus B.V.NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNon-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and terminated194
2026-10 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06474468 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal CancerAdvanced or Metastatic Esophageal Cancerunknown148
2026-10 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06423885 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction AdenocarHER2-positive Gastric or Gastroesophageal Junction Adenocarcinomaactive not recruiting64
2026-09-28P3Cinclus Pharma Holding ABNCT07037875 A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux DiseaGERD (Gastroesophageal Reflux Disease)completed523
2026-09 est.P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767800 A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally AdvanGastroesophageal Adenocarcinomarecruiting204
2026-08-31P3Daewon Pharmaceutical Co., Ltd.NCT07931521 Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux DiseaseErosive Reflux Disease; GERD (Gastroesophageal Reflux Disease)completed328
2026-08-31 est.P3Daiichi SankyoNCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-CGastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinomaactive not recruiting490
2026-08-26 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06577376 A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaLocalized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma;not yet recruiting252
2026-08-14P2AstraZeneca AZNNCT07143604 A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.Gastric Cancer; Gastroesophageal Junction Canceractive not recruiting33
2026-08 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07110571 A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerGastric Cancer; Gastroesophageal-junction Cancerrecruiting200
2026-07-22P3Hoffmann-La RocheNCT04543617 A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed FolloEsophageal Squamous Cell Carcinomacompleted760
2026-07-21P2Takeda TAKNCT02616302 A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years OldGastroesophageal Reflux Disease (GERD)completed71
2026-07-15P3Jazz Pharmaceuticals JAZZNCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinomaactive not recruiting920
2026-06-30 est.P3Onconic Therapeutics Inc.NCT07160790 Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux DiseaseNon-erosive Gastroesophageal Reflux Diseasenot yet recruiting321
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-05-31P3AstraZeneca AZNNCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdGastric Cancer; Gastroesophageal Junction Canceractive not recruiting594
2026-05-27P2Microbiome Health SciencesNCT05556824 Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERDGastroesophageal Refluxcompleted255

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "esophageal cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.